Sight Sciences (NASDAQ:SGHT) Announces Quarterly Earnings Results

Sight Sciences (NASDAQ:SGHT) posted its quarterly earnings results on Wednesday. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.10, FiscalAI reports. The business had revenue of $23.39 million during the quarter, compared to analysts’ expectations of $21.72 million. Sight Sciences had a negative net margin of 35.69% and a negative return on equity of 41.99%.

Here are the key takeaways from Sight Sciences’ conference call:

• Positive Sentiment: Second-quarter revenue increased 20% year over year to $23.4 million, driven by growth in both interventional glaucoma and dry eye; net loss improved 63% to $4.4 million.
• Positive Sentiment: Management raised 2026 revenue guidance to $88 million–$92 million and lowered adjusted operating expense guidance to $92 million–$94 million, citing stronger execution and continued expense discipline.
• Positive Sentiment: TearCare dry-eye revenue nearly doubled sequentially to a record $2.7 million, with ordering accounts rising to 176 and covered lives increasing to approximately 14.5 million. The company expects reimbursement-related momentum to build in the second half, although additional payer wins are not included in guidance.
• Positive Sentiment: OMNI glaucoma revenue grew 8% year over year, while active accounts reached a record and utilization recovered to its highest level since late 2024. Aetna added roughly 25 million covered lives, and the company plans a staged OMNI Ultra rollout beginning before its full launch at the AAO meeting and broader adoption in 2027.
• Negative Sentiment: Cash declined to $79.8 million after a $5.4 million Alcon litigation-related success-fee payment; the company also faces ongoing legal uncertainty as Alcon appeals the judgment, which included approximately $55 million in damages and interest plus future royalties.

Sight Sciences Price Performance

SGHT stock traded up $0.41 during midday trading on Friday, hitting $7.50. 286,819 shares of the stock were exchanged, compared to its average volume of 270,499. The stock’s 50-day moving average price is $5.18 and its 200-day moving average price is $4.90. The company has a debt-to-equity ratio of 0.68, a quick ratio of 5.48 and a current ratio of 5.86. The stock has a market cap of $407.86 million, a price-to-earnings ratio of -13.44 and a beta of 2.38. Sight Sciences has a fifty-two week low of $3.19 and a fifty-two week high of $9.24.

Analysts Set New Price Targets

A number of brokerages have issued reports on SGHT. Weiss Ratings lowered shares of Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Citigroup raised their price target on shares of Sight Sciences from $5.15 to $6.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Finally, UBS Group upped their price objective on Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Thursday. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Sight Sciences currently has a consensus rating of “Hold” and an average target price of $7.88.

Insider Buying and Selling at Sight Sciences

In other news, CFO James Rodberg sold 6,902 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $5.36, for a total value of $36,994.72. Following the sale, the chief financial officer directly owned 224,037 shares in the company, valued at $1,200,838.32. This represents a 2.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeremy B. Hayden sold 12,733 shares of Sight Sciences stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.51, for a total value of $70,158.83. Following the transaction, the insider owned 357,037 shares of the company’s stock, valued at $1,967,273.87. This represents a 3.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 58,566 shares of company stock valued at $318,827. Insiders own 30.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. AQR Capital Management LLC purchased a new stake in Sight Sciences during the first quarter worth approximately $128,000. Strs Ohio purchased a new position in shares of Sight Sciences in the 1st quarter valued at $158,000. Rhumbline Advisers lifted its holdings in shares of Sight Sciences by 9.5% during the 1st quarter. Rhumbline Advisers now owns 49,797 shares of the company’s stock valued at $120,000 after acquiring an additional 4,319 shares in the last quarter. Geode Capital Management LLC boosted its position in Sight Sciences by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 845,776 shares of the company’s stock worth $3,494,000 after purchasing an additional 43,791 shares during the period. Finally, XTX Topco Ltd acquired a new stake in Sight Sciences in the 2nd quarter valued at $67,000. 55.51% of the stock is owned by hedge funds and other institutional investors.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.